NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN) and NewAmsterdam Pharma Company (NAMS...

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and NewAmsterdam Pharma Company (NAMS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dyne Therapeutics (DYN), NewAmsterdam Pharma Company...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NAMS	$21.93	+3.54%	2.31M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NAMS	$21.93	+3.5%	2.31M
3
4
5
6

NAMS

Get NewAmsterdam Pharma Company N.V. Data in Excel

Get NewAmsterdam Pharma Company N.V. Data in Excel